About the Authors
- John Marshall
-
* E-mail: john.marshall@genzyme.com
Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America
- Karen M. Ashe
-
Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America
- Dinesh Bangari
-
Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America
- KerryAnne McEachern
-
Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America
- Wei-Lien Chuang
-
Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America
- Joshua Pacheco
-
Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America
- Diane P. Copeland
-
Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America
- Robert J. Desnick
-
Affiliation Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, United States of America
- James A. Shayman
-
Affiliation Internal Medicine – Nephrology, Genzyme Corporation, University of Michigan, Ann Arbor, Michigan, United States of America
- Ronald K. Scheule
-
Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America
- Seng H. Cheng
-
Affiliation Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, United States of America
Competing Interests
The authors have read the journal's policy and have the following conflicts: John Marshall, Karen Ashe, Dinesh Bangari, Kerry Anne McEachern, Wei-Lien Chuang, Joshua Pacheco, Diane Copeland, Ronald Scheule, and Seng Cheng are all employees of and shareholders in Genzyme Corporation. James Shayman is an employee of the University of Michigan and co-inventor of Genz-112638 which is licensed to Genzyme by the University of Michigan. Genzyme funded all the studies and is developing Eliglustat tartrate for treatment of type 1 Gaucher disease. Patents regarding this approach have been filed. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JM KMA DB KM DPC JAS RKS SHC. Performed the experiments: JM KMA DB KM WC JP. Analyzed the data: JM KMA DB WC JP DPC RJD JAS RKS SHC. Contributed reagents/materials/analysis tools: JM DB WC DPC RJD JAS. Wrote the paper: JM RKS SHC.